ADVANCED BREAST CANCER

This early-phase study tests a new drug called BGB-43395 in people with advanced HR+/HER2- breast cancer and other solid tumors. The drug blocks a protein (CDK4) that helps cancer cells grow. Researchers want to find the safest and most effective dose, either alone or combined wi…

This early-phase study tests a new drug called BMS-986500 in people with advanced solid tumors or breast cancer that has stopped responding to standard treatments. The main goals are to check safety and find the right dose. About 234 adults will take part, receiving the drug alon…

This study compares two ways of taking the drug pyrotinib for people with HER2-positive advanced breast cancer: taking it every day (continuous) or taking breaks (intermittent). The goal is to see which schedule works better and has fewer side effects. About 186 adults whose canc…

This study tests two experimental drugs, MHB036C and MHB039A, given together to people with advanced breast cancer or other advanced solid tumors that have spread. The goal is to see if the combination is safe and can shrink tumors. About 210 adults aged 18 to 75 with measurable …

This early-stage study tests a new drug called MEN2312 in 240 adults with advanced breast cancer that has spread and cannot be cured. The drug targets a protein (KAT6) that may help control cancer growth. The main goals are to find the safest dose and check for side effects, whil…

This phase 3 study tests whether adding capivasertib to standard hormone therapy helps people with HR+/HER2- advanced breast cancer stay on treatment longer and maintain quality of life. About 250 adults whose cancer worsened after prior hormone therapy will take capivasertib plu…

This early-phase study tests an experimental oral drug, RGT-490, in adults with advanced solid tumors (including breast, ovarian, and endometrial cancers) that have a specific genetic change called PIK3CA. The main goals are to check safety, find the right dose, and see if the dr…

This study tests two experimental drugs, camizestrant and atirmociclib, in 24 people with a specific type of advanced breast cancer (ER-positive, HER2-negative) that has worsened after prior treatment. The main goal is to check safety and how the body processes the drugs, with ea…

This study looks at whether giving a second course of antibody-drug conjugates (ADCs) can safely shrink tumors in people with advanced breast cancer who have already received these drugs. About 160 adults with metastatic breast cancer will receive the same or a different ADC and …

This study tests a new drug combination (RLY-2608 plus fulvestrant) against another combination (capivasertib plus fulvestrant) in people with a specific type of advanced breast cancer (HR+/HER2-) that has a PIK3CA gene mutation. The cancer has returned or worsened after prior tr…

This study tests a new drug called ETX-636 for people with advanced solid tumors (like breast cancer) that have a specific change in the PIK3CA gene. The drug is given alone or with another cancer medicine. The goal is to see if it is safe and helps shrink tumors. About 233 adult…

This early-stage trial tests a new drug called metarrestin in people with solid tumors that have spread. The goal is to find a safe dose and see if it can shrink tumors or stop them from growing further. Adults with certain cancers and children aged 12-17 with solid tumors may jo…

This study tests a drug called ZOLADEX 10.8 mg in premenopausal women with a certain type of advanced breast cancer (HR+/HER2-). The goal is to see if the drug can safely and effectively stop the ovaries from producing hormones that may fuel the cancer. About 88 women aged 18 to …

This early-stage trial tests a new treatment called X-PACT for people with advanced head and neck cancer, breast cancer, soft tissue sarcoma, or melanoma that has not responded to standard therapies. The treatment involves injecting a special drug and device directly into the tum…

This study compares a combination of two chemotherapy drugs (capecitabine and cyclophosphamide) against the doctor's choice of treatment as maintenance therapy for people with advanced breast cancer. Participants must have their disease under control after initial treatment. The …

This study tests whether adding a trastuzumab biosimilar (SB3) to the chemotherapy drug eribulin helps control advanced HER2-positive breast cancer better than eribulin alone. The trial enrolls 180 adults whose cancer has returned or spread and who have already tried at least two…

This early-stage study tests a new oral drug, BBI-940, in people with advanced or metastatic breast cancer that has not responded to standard treatments. The drug works by breaking down a protein that helps cancer cells grow. The study aims to find the safest dose and check for s…

This study tests a new combination of two drugs (saruparib and camizestrant) against standard treatments for advanced breast cancer that is hormone-receptor-positive and HER2-negative. It is for people with inherited BRCA1, BRCA2, or PALB2 mutations. The goal is to see if the new…

This study tests a new drug called OP-1250 (palazestrant) against the usual treatments (fulvestrant or an aromatase inhibitor) in people with a certain type of advanced breast cancer (ER+, HER2-). The goal is to see if OP-1250 can slow cancer growth better than standard care. The…

This study tests a drug called Disitamab vedotin in people with advanced breast cancer that has low levels of a protein called HER2. Participants must have had no more than one prior chemotherapy and never used this type of drug before. The goal is to see if the drug can shrink t…

This study looks at how well the drug dalpiciclib works and how safe it is for people with a certain type of advanced breast cancer (HR+/HER2-). About 103 participants will take the drug, and researchers will track how long the cancer stays under control and what side effects occ…

This early-stage study tests a new cancer pill, PF-08032562, in people with advanced breast or colorectal cancer that has spread. The goal is to find the safest dose and see how well it works, either alone or with other treatments. About 260 adults will take the pill daily in 28-…

This study tests whether the drug sacituzumab govitecan (SG) can still shrink tumors in people with a certain type of advanced breast cancer (HR+/HER2 low or ultra low) who have already received a similar drug called T-DXd. About 75 adults will take part. The goal is to see if us…

This study tests a new drug called QL1706 in people with a common type of advanced breast cancer (HR+/HER2-). The goal is to see if it can slow down the cancer's growth and check for side effects. About 123 women will take part, and the results will be compared to standard care.

This early-stage study tests a new treatment for advanced breast cancer using a patient's own immune cells, called tumor-infiltrating lymphocytes (TILs). These cells are taken from a tumor sample, grown in a lab, and then given back to the patient. The goal is to see if this ther…

This study tests whether adding everolimus to elacestrant can help people with a certain type of advanced breast cancer (ER+/HER2- with an ESR1 mutation) live longer without their cancer getting worse. About 240 adults whose cancer has stopped responding to standard hormone thera…

This study is testing a drug called trastuzumab deruxtecan in 118 adults with advanced breast cancer. The goal is to see how long the drug can keep the cancer from growing and what side effects occur. Participants must be in good overall health (ECOG 0-1) and not pregnant or nurs…

This study tests whether adding an immunotherapy drug called toripalimab to standard chemotherapy can help shrink tumors or slow disease in people with advanced HER2-negative breast cancer. About 92 adults whose cancer has worsened after prior treatments will receive the combinat…

This study tests a new combination of drugs for people with advanced breast or stomach cancers that have a protein called HER2. The experimental drug disitamab vedotin is designed to stick to cancer cells and kill them, and it is combined with the approved drug tucatinib. The goa…

This early-phase study tests a new drug called BBO-10203 in people with advanced solid tumors that have not responded to other treatments. The drug works by blocking a key cancer growth signal. The main goals are to find the safest dose and check for side effects, both when given…

This study tests a drug called trastuzumab deruxtecan (T-DXd) against the usual treatment (a CDK4/6 inhibitor plus hormone therapy) for people with a certain type of advanced breast cancer. The cancer must be hormone receptor-positive, HER2-low or ultralow, and have a specific ge…

This study tests whether certain drug combinations can help people with advanced ER+ breast cancer whose previous treatment (a CDK4/6 inhibitor) has stopped working. About 135 postmenopausal women will receive a treatment chosen based on their tumor's genetic makeup. The goal is …

This study tests a two-step treatment plan for people with advanced breast cancer that is hormone-receptor-positive and HER2-low or ultra-low. First, they receive a targeted drug called trastuzumab rezetecan for several months. Then, they switch to a combination of a CDK4/6 inhib…

This study tests a new drug, RLY-2608, designed to block a specific cancer-driving mutation (PIK3CA) in people with advanced solid tumors or breast cancer. The drug is given alone or combined with hormone therapy and other targeted drugs. The goal is to find the safest dose and s…

This study tests an experimental drug called patritumab deruxtecan in people with advanced breast cancer that no longer responds to hormone therapy. About 99 participants will receive the drug every three weeks to see if it shrinks tumors. Researchers will also study how the drug…

This study tests whether a smartphone app that lets cancer patients report their symptoms, combined with regular calls from a specially trained nurse, can help them better manage chemotherapy side effects and improve their quality of life. The study includes 414 adults with early…

This study explores whether regular video or phone check-ins between hospice patients with advanced breast cancer and their oncology team can improve the hospice experience. About 200 participants, along with their caregivers and nurses, will take part. The goal is to see if this…

This study tests a new telehealth program called ENGAGE for people with stage IV breast, prostate, lung, or colorectal cancer. The program aims to reduce how much symptoms like pain, fatigue, and distress interfere with daily life. About 190 participants will be randomly assigned…

This study looks at 100 adults with advanced breast cancer to see if a special type of PET-CT scan (called F-18 FDG PET-CT) is better than standard imaging at tracking how well the first round of cancer treatment is working. Participants will have both types of scans over 48 week…

This study is for people with advanced breast, stomach, bladder, or lung cancer who are receiving a type of targeted treatment called an antibody-drug conjugate (ADC). The goal is to understand why some tumors stop responding to this therapy. Researchers will compare tumor sample…